-
2025-522979-29-00
5
2026-04-30
Acute myeloid leukemia
-
2023-509220-17-00
7
2026-04-10
Metastatic solid tumors
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-511989-36-00
5
2025-09-24
Ewing Sarcoma
-
2024-514440-86-00
4
2025-08-04
Relapse/Refractory Large B Cell Lymphoma
-
2024-513112-99-00
5
2025-06-13
Active Psoriatic Arthritis Stratified by Prior Biologic Use
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-514953-31-00
4
2025-05-20
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
-
2024-517513-32-00
5
2025-05-16
Sjögren’s Syndrome
-
2024-516219-25-00
5
2025-03-25
psoriatic arthritis
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-519969-21-00
6
2025-01-01
Infective endocarditis
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2022-501697-19-01
5
2024-06-18
Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2022-502357-34-00
5
2023-09-27
Extensive Stage Small Cell Lung Cancer
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma